The number of reported cases of iatrogenic demyelination of the central nervous system (CNS) is on the rise. This is, in part, related to the recent expansion in the use of biologics. Review of literature from the past decade suggests that in addition to vaccines, tumor necrosis factor (TNF)-alpha inhibitors and checkpoint inhibitors are the most frequently cited inducers of central inflammation. About one-third of demyelinating cases in the setting of TNF-alpha inhibitors evolve into full-blown multiple sclerosis. In addition to demyelination, checkpoint inhibitors may also cause accelerated paraneoplastic encephalitis and other antibody-mediated conditions. Luckily, the overall prognosis of iatrogenic central inflammation is favorable, with most cases having partial or complete response to steroids and discontinuation of the offending agent. Long-term monitoring and initiation of maintenance immune-modulating therapy may be necessary in some patients. In this article, we provide an updated review of biologic-induced inflammation of the CNS.
HohlfeldR.Inhibitors of tumor necrosis factor-alpha: Promising agents for the treatment of multiple sclerosis. Mult Scler1996; 1(6): 376–378.
7.
KolliasGDouniEKassiotisGet al. On the role of tumor necrosis factor and receptors in models of multiorgan failure, rheumatoid arthritis, multiple sclerosis and inflammatory bowel disease. Immunol Rev1999; 169: 175–194.
8.
The Lenercept Multiple Sclerosis Study Group and the University of British Columbia MS/MRI Analysis Group. TNF neutralization in MS: Results of a randomized, placebo-controlled multicenter study. Neurology1999; 53(3): 457–465.
9.
van OostenBWBarkhofFTruyenLet al. Increased MRI activity and immune activation in two multiple sclerosis patients treated with the monoclonal anti-tumor necrosis factor antibody cA2. Neurology1996; 47(6): 1531–1534.
FischerRKontermannREMaierO.Targeting sTNF/TNFR1 signaling as a new therapeutic strategy. Antibodies2015; 4: 48–70.
12.
PfuellerCFSeipeltEZippFet al. Multiple sclerosis following etanercept treatment for ankylosing spondylitis. Scand J Rheumatol2008; 37(5): 397–399.
13.
BarrerasPMealyMAPardoCA.TNF-alpha inhibitor associated myelopathies: A neurological complication in patients with rheumatologic disorders. J Neurol Sci2017; 373: 303–306.
14.
ThompsonAJBanwellBLBarkhofFet al. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol2018; 17(2): 162–173.
15.
Cruz Fernández-EsparteroMPérez-ZafrillaBNaranjoAet al. Demyelinating disease in patients treated with TNF antagonists in rheumatology: Data from BIOBADASER, a pharmacovigilance database, and a systematic review. Semin Arthritis Rheum2011; 41(3): 524–533.
16.
SeyfertSKlappsPMeiselCet al. Multiple sclerosis and other immunologic diseases. Acta Neurol Scand1990; 81(1): 37–42.
DineJGordonRShamesYet al. Immune checkpoint inhibitors: An innovation in immunotherapy for the treatment and management of patients with cancer. Asia Pac J Oncol Nurs2017; 4(2): 127–135.
19.
JenkinsRWBarbieDAFlahertyKT.Mechanisms of resistance to immune checkpoint inhibitors. Br J Cancer2018; 118(1): 9–16.
20.
GranierCDe GuillebonEBlancCet al. Mechanisms of action and rationale for the use of checkpoint inhibitors in cancer. ESMO Open2017; 2(2): e000213.
21.
Suarez-AlmazorMEKimSTAbdel-WahabNet al. Review: Immune-related adverse events with use of checkpoint inhibitors for immunotherapy of cancer. Arthritis Rheumatol2017; 69(4): 687–699.
22.
SpainLWallsGJulveMet al. Neurotoxicity from immune-checkpoint inhibition in the treatment of melanoma: A single centre experience and review of the literature. Ann Oncol2017; 28(2): 377–385.
23.
HaanenJBAGCarbonnelFRobertCet al. Management of toxicities from immunotherapy: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol2017; 28(suppl_4): iv119–iv142.
24.
GillCRouseSJacobsonRD.Neurological complications of therapeutic monoclonal antibodies: Trends from oncology to rheumatology. Curr Neurol Neurosci Rep2017; 17(10): 75.
25.
HurwitzAASullivanTJKrummelMFet al. Specific blockade of CTLA-4/B7 interactions results in exacerbated clinical and histologic disease in an actively-induced model of experimental allergic encephalomyelitis. J Neuroimmunol1997; 73(1–2): 57–62.
26.
CaoYNylanderARamananSet al. CNS demyelination and enhanced myelin-reactive responses after ipilimumab treatment. Neurology2016; 86(16): 1553–1556.
27.
LarkinJChmielowskiBLaoCDet al. Neurologic serious adverse events associated with nivolumab plus ipilimumab or nivolumab alone in advanced melanoma, including a case series of encephalitis. Oncologist2017; 22(6): 709–718.
28.
BossartSThurneysenSRushingEet al. Case report: Encephalitis, with brainstem involvement, following checkpoint inhibitor therapy in metastatic melanoma. Oncologist2017; 22(6): 749–753.
29.
WilliamsTJBenavidesDRPatriceKAet al. Association of autoimmune encephalitis with combined immune checkpoint inhibitor treatment for metastatic cancer. JAMA Neurol2016; 73(8): 928–933.
NarumiYYoshidaRMinamiYet al. Neuromyelitis optica spectrum disorder secondary to treatment with anti-PD-1 antibody nivolumab: The first report. BMC Cancer2018; 18(1): 95.
34.
CarlDGrullichCHeringSet al. Steroid responsive encephalopathy associated with autoimmune thyroiditis following ipilimumab therapy: A case report. BMC Res Notes2015; 8: 316.
35.
DavisTEKis-TothKSzantoAet al. Glucocorticoids suppress T cell function by upregulating microRNA 98. Arthritis Rheum2013; 65(7): 1882–1890.
36.
ThompsonJA.New NCCN guidelines: Recognition and management of immunotherapy-related toxicity. J Natl Compr Canc Netw2018; 16(5S): 594–596.
37.
KolbNATrevinoCRWaheedW.Neuromuscular complications of immune checkpoint inhibitor therapy. Muscle Nerve. Epub ahead of print 17 January 2018. DOI: 10.1002/mus.26070.
38.
BeaucheminPCarruthersR.MS arising during tocilizumab therapy for rheumatoid arthritis. Mult Scler2016; 22(2): 254–256.
39.
WhitlockJEidelmanBWhitlockJet al. Demyelinating disease and axonal peripheral neuropathy in a 68-year old male treated with tocilizumab for rheumatoid arthritis. Muscle Nerve2015; 52(S2): S129.
40.
ZhouYZhangYYangXet al. Retrobulbar optic neuritis in a bevacizumab-treated patient with metastatic breast cancer. Breast J2012; 18(5): 502–503.
41.
RiceCMRossiterDFehmiJet al. Tumefactive demyelination presenting during bevacizumab treatment. BMJ Case Rep2015; 2015: bcr2015212173.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
